Overall Survival Outcome In Patients With New Treatment Approaches For Glioblastoma Multiforme In Randomized Controlled Trials (P3-13.004)

Abstract

<h3>Objective:</h3> ○ Analyze and compare <b>the current standard treatment</b> for <b>glioblastoma multiforme</b> with <b>new treatment approaches</b> with an emphasis on overall survival in <b>randomized controlled trials</b>. <h3>Background:</h3> ○ <b>Glioblastoma multiforme</b> is the most common malignant brain tumor in adults, accounting for approximately 16% of all CNS neoplasms. The <b>current standard treatment</b> for glioblastoma consists of maximal surgical resection, radiotherapy and concomitant or adjuvant chemotherapy with temozolomide. While overall mortality remains high, the understanding of gene mutations and molecular mechanisms combined with clinical trials are opening new ways to approach this disease. <h3>Design/Methods:</h3> The search in <b>PUBMED/MEDLINE</b> included the keywords: “<b>Glioblastoma</b>”, “ <b>Temozolomide</b>”, resulting in 2,618 articles, the filter of the last 5 years was applied as well as randomized clinical trials, this yielded 37 results. A reading of the abstract and title was made. Referenced articles were also used. Finally, 12 articles were used. Subsequent analysis was performed with <b>PRISMA</b>. <h3>Results:</h3> Among the new treatment approaches, the use of Tumor – treating fields <b>(TTFields)</b> plus <b>temozolomide</b> increases progression free survival and overall survival compared to standard of care, while therapies such as <b>ipilimumab</b> plus <b>temozolomide</b> and <b>velipaprib</b> did not show significant differences in overall survival, progression free survival rate did not improve compared to the use of <b>radiotherapy</b> and <b>concomitant or adjuvant chemotherapia</b> with <b>temozolomide</b>. <h3>Conclusions:</h3> To summarize up due to the high mortality associated with glioblastoma, a search for efficacy of alternative treatments is necessary. The effect of different treatment strategies on survival and other health outcomes remains largely unknown, although in treating fields (TTFields) there was a statistically significant increase in survival, it is an efficient and safe treatment that will increase the overall survival in this disease where recurrence and lethality are high and where the quality and lengthening of life become the central axis. <b>Disclosure:</b> Ms. Castillo Vaca has nothing to disclose. Dr. Arreola Flores has nothing to disclose. Dr. Bermudez-Faz has received publishing royalties from a publication relating to health care. Dr. Chavez has nothing to disclose. Dr. Chavez has nothing to disclose. Mr. Carrillo Rodríguez has nothing to disclose. Ms. Estrada Posadas has nothing to disclose. Miss Estrada Ortega has nothing to disclose. Miss Rojas Martínez has nothing to disclose. Mr. Zamorano has nothing to disclose.